-+ 0.00%
-+ 0.00%
-+ 0.00%

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

Barchart·09/30/2026 11:51:00
Listen to the news

Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST v1.1.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.